Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities
Lifeward Ltd. a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced the expansion of patient access to the ReWalk Personal Exoskeleton through a new international distribution agreement with Verita Neuro, a Verita Healthcare Ltd. company. This collaboration supports Lifeward’s long-term growth strategy by extending its commercial footprint into new international markets through a partner-led, capital-efficient model. Verita Neuro has an established international footprint, with the partnership launching across multiple international geographies. Verita Neuro will be the exclusive distributor of ReWalk initially in Mexico, Thailand, and the United Arab Emirates, where it has advanced centers that offer innovative treatments for people living with neurological and spinal cord injuries.
Health Technology Insights: MindWalk Achieves Record Growth and Advances AI Asset Pipeline
Verita Neuro offers unparalleled reach through its international database of over 25,000 spinal cord injury patients plus a growing network of international rehabilitation centers able to deliver highly personalized care.
Health Technology Insights: Hercules Pharmaceuticals Appoints Ali Ahmed as Chief Commercial Officer
“This latest distribution agreement with Verita Neuro is consistent with Lifeward’s strategy to expand global access to the ReWalk Personal Exoskeleton for patients with spinal cord injury, building our established distribution and reimbursement presence in the United States and Germany,” said Mark Grant, CEO of Lifeward. “The Company’s hybrid commercial model, combining direct sales in the United States with third-party distribution and servicing in select international markets, is intended to support increased sales volumes while managing operating expenses and advancing long-term, sustainable growth.”
Lifeward selected Verita as its partner in these targeted regions to integrate ReWalk into their multi-modal treatment methodologies for people living with neurological and spinal cord injuries. Today, Verita Neuro modalities include surgical neural stimulation, stem cell therapy, and neurorehabilitation.
Verita’s CEO, Julian Andriesz, commented, “As the global pioneer in neurological restoration, Verita Neuro redefined epidural stimulation reconnecting brain-body pathways to regain voluntary movement and vital autonomic functions. We are excited to empower our patients with the most cutting-edge robotic physical rehabilitation systems. Through Lifeward’s ReWalk exoskeleton in our in-patient program, we’re achieving another world first, seamless multimodal enablement.”
Verita will be performing patient-specific setup and training in the ReWalk Personal Exoskeleton in an intensive, daily, in-patient neurorehabilitation program. This new delivery method is an alternative to the current protocol of outpatient training and rehabilitation. We expect this progressive intensive in-patient program will support clinical adoption in physical rehabilitation settings across a range of patient cases and global markets.
Health Technology Insights: GenSci and RTW Partner on GS-098 for Graves’ and Eye Disease
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- GlobeNewswire
